塞力医疗最新股价为31.52元，较前一交易日上涨2.87元，涨幅10.02%。开盘价为28.49元，最高触及 31.52元，最低下探至27.69元，成交量为61.43万手，成交额达18.61亿元。 塞力医疗属于医药商业板块，公司业务涵盖医疗检验集约化服务、体外诊断产品供应及医疗信息化建 设。近年来，公司逐步拓展创新药领域，并受益于行业政策支持。 资金方面，塞力医疗8月22日主力资金净流入5.05亿元，占流通市值的8.39%；近五日主力资金累计净流 入7.32亿元，占流通市值的12.16%。 消息面上，国家医保局与卫健委近期印发《支持创新药高质量发展的若干措施》，提出增设商业健康保 险创新药品目录，支持创新药进入医保及商保目录。此外，国内创新药企业出海进展加快，行业基本面 迎来改善。 风险提示：市场有风险，投资需谨慎。 来源:金融界 ...

Core Insights - The pharmaceutical commercial sector experienced a slight increase of 0.05% on August 22, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Group 1: Stock Performance - Saily Medical (603716) saw a closing price of 31.52, with a significant increase of 10.02% and a trading volume of 614,300 shares, resulting in a transaction value of 1.861 billion yuan [1] - Guofang Co. (600538) closed at 6.55, up 2.18%, with a trading volume of 218,500 shares [1] - Runda Medical (603108) closed at 18.35, up 1.94%, with a trading volume of 303,900 shares [1] - Other notable stocks include Jiuzhoutong (600998) with a slight increase of 0.55% and Yifeng Pharmacy (603939) with a minimal increase of 0.20% [1] Group 2: Capital Flow - The pharmaceutical commercial sector saw a net inflow of 363 million yuan from main funds, while retail investors experienced a net outflow of 114 million yuan [2] - Speculative funds recorded a net outflow of 249 million yuan [2]

格隆汇8月22日丨柳药集团(603368.SH)公布，截至2025年8月22日，公司通过集中竞价交易方式回购股 份数量为437.38万股，已回购股份占公司目前总股本的比例为1.10%，回购成交的最高价为18.60元/股、 最低价为18.22元/股，已支付的总金额为8,073.03万元（不含交易费用）。 ...

金融界消息 截至2025年8月22日收盘，百花医药（600721）报收于8.75元，上涨1.51%，换手率 10.64%，成交量40.90万手，成交金额3.57亿元。 资金流向方面，今日主力资金净流入4148.32万元，占比成交额11.63%。其中，超大单净流入1511.91万 元、占成交额4.24%，大单净流入2636.41万元、占成交额7.39%，中单净流出流入913.74万元、占成交 额2.56%，小单净流出5062.06万元、占成交额14.19%。 百花医药最新一期业绩显示，截至2025中报，公司营业总收入2.02亿元、同比增长2.95%，归属净利润 2548.34万元，同比增长12.45%，扣非净利润2405.87万元，同比增长13.82%，流动比率2.026、速动比率 1.722、资产负债率29.66%。 天眼查商业履历信息显示，新疆百花村医药集团股份有限公司，成立于1996年，位于自治区直辖县级行 政区划，是一家以从事批发业为主的企业。企业注册资本38169.2645万人民币，实缴资本4811.53万人民 币。公司法定代表人为郑彩红。 通过天眼查大数据分析，新疆百花村医药集团股份有限公司共对外投 ...

Group 1 - The core viewpoint of the news is that Huaren Health has seen a consistent inflow of financing over the recent trading days, indicating investor interest [1][2]. - On August 21, Huaren Health recorded a financing buy amount of 0.24 billion, ranking 2046 in the market, with a financing repayment amount of 0.19 billion, resulting in a net buy of 5.52 million [1]. - Over the three trading days from August 18 to August 21, Huaren Health received financing buys of 0.18 billion, 0.25 billion, and 0.24 billion respectively, showing a stable trend in financing activity [2]. Group 2 - In terms of securities lending, on the same day, there were no shares sold or net sold, indicating no activity in this area for Huaren Health [3].

据证券之星公开数据整理，近期国药股份（600511）发布2025年中报。截至本报告期末，公司营业总收 入256.34亿元，同比上升3.54%，归母净利润9.49亿元，同比下降5.19%。按单季度数据看，第二季度营 业总收入129.21亿元，同比上升2.27%，第二季度归母净利润4.9亿元，同比下降9.52%。本报告期国药 股份应收账款上升，应收账款同比增幅达49.79%。 本次财报公布的各项数据指标表现一般。其中，毛利率6.14%，同比减13.32%，净利率3.87%，同比减 9.98%，销售费用、管理费用、财务费用总计4.95亿元，三费占营收比1.93%，同比减10.89%，每股净资 产23.16元，同比增8.37%，每股经营性现金流-2.0元，同比减41.69%，每股收益1.26元，同比减5.2% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 247.57 Z | 256.34亿 | 3.54% - | | 归母净利润（元） | 10.01亿 | 2656 | -5.19% | | 扣非净利润(元) | 1 ...

证券代码：600713 证券简称：南京医药 编号：ls2025-109 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于挂牌出租南京市秦淮区延龄巷27号房地产的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 南京医药股份有限公司（以下简称"公司"）在南京市公共资源交易中心以公开挂牌方式出租权属于公司 的南京市秦淮区延龄巷27号房地产（以下简称"标的资产"）。 2025年8月20日，公司收到南京市公共资 源交易中心《国有企业房产出租成交确认书》，确认本次挂牌承租方为万谷企业管理集团有限公司（以 下简称"万谷公司"），现将具体进展情况公告如下： 一、挂牌出租标的资产的审议程序 万谷企业管理集团有限公司 住所：南京市雨花台区小行路16号 法定代表人：金平 注册资本：6,666.67万元 2025年6月23-25日，公司第十届董事会临时会议审议通过《关于公司公开挂牌出租南京市秦淮区延龄巷 27号房地产的议案》。董事会同意公司公开挂牌出租标的资产，挂牌出租起始年租金租赁价格为711.55 万元/年（人民币 ...

Group 1 - The stock price of Zhongyao Holdings is reported at 5.42 yuan, down 0.01 yuan from the previous trading day, with a decline of 0.18% [1] - The company operates in the pharmaceutical commercial sector, primarily engaged in the wholesale and retail of drugs and medical devices [1] - The actual controller of the company is the State-owned Assets Supervision and Administration Commission of the State Council, with business coverage across multiple regions in the country [1] Group 2 - Chongqing Yijian, the controlling shareholder, transferred 24% of its equity for 2.206 billion yuan to the General Technology Group, making it the largest shareholder of Chongqing Yijian, although the control of the company remains unchanged [1] - In the first half of the year, the company achieved revenue of 41.188 billion yuan and a net profit attributable to shareholders of 282 million yuan, representing a year-on-year growth of 18.56% [1] Group 3 - Today, the main funds of Zhongyao Holdings experienced a net outflow of 18.1607 million yuan, with a cumulative net outflow of 14.7787 million yuan over the past five days [1]

Group 1 - The company, Nanjing Pharmaceutical Co., Ltd., is issuing its third short-term financing bond for 2024, with a total issuance amount of 50 million yuan [1] - The bond, named "24 Nanjing Pharmaceutical SCP003," has an interest rate of 1.8% and a maturity period of 269 days, with the principal and interest repayment date set for September 12, 2025 [1] - The bond's repayment amount is expected to be approximately 50.66329 million yuan, subject to final confirmation [1] Group 2 - The bond's funds will be transferred to the designated account of the Interbank Market Clearing House before the repayment date, and the clearing house will then distribute the funds to bondholders [1] - In case the repayment date falls on a public holiday, the payment will be postponed accordingly [1] - Bondholders must notify the Interbank Market Clearing House of any changes to their fund transfer paths before the repayment date to avoid any delays in receiving funds [1]

证券代码：600713 证券简称：南京医药 编号：ls2025-108 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为保证南京医药股份有限公司 2025 年度第二期超短期融资券（债券简称：25 南京医药 SCP002，债券代码：012580666）兑付工作的顺利进行，现将有关事宜 公告如下： 一、本期债券基本情况 发行人名称 南京医药股份有限公司 超短期融资券 | 债项简称 | 25 南京医药 | SCP002 | | --- | --- | --- | | 债项代码 | 012580666 | | | 发行金额（万元） | 50,000 | | | 起息日 | 2025-03-17 | | | 发行期限 | 179 天 | | | 债项余额（万元） | 50,000 | | | 最新评级情况 | / | | | 偿还类别 | 本息兑付 | | | 本计息期债项利率 | 1.94% | | | 本息兑付日 | 2025-09-12 | | | 本期应偿付本息 ...